For CVS Health CVS, the key to building customer trust is to enhance access to life-changing medications and also make them affordable. Beginning July 1, the company’s Pharmacy Benefit Manager (“PBM”) ...

CVS Caremark’s decision to place Wegovy over Zepbound could give Novo an edge as the companies fight to convince insurance companies to pay for their treatments, which cost more than $1,000 a ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

Summary. Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025.

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's Wegovy for weight loss — a major blow to the Indianapolis pharmaceutical ...

On July 1, Caremark will no longer prefer Zepbound in its standard formulary, replacing the drug instead with Novo Nordisk’s Wegovy. ... CVS Caremark was able to do what PBMs do best: ...

CVS’s drug-benefits unit, known as Caremark, earlier this month negotiated a deal to make Novo’s Wegovy more widely available to its customers — knocking Eli Lilly & Co.’s Zepbound off its ...

Caremark will also drop the weight loss drug Zepbound from its standard formularies on that date, in a blow to its manufacturer, Eli Lilly, a CVS spokesperson told CNBC.

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template ... which began selling higher doses of Zepbound, a weight loss drug, ...

CVS Caremark, the largest pharmacy ... with Zepbound leading to greater weight loss than Wegovy and with Lilly having what look to be more promising injectable and oral candidates in its pipeline.

Caremark will also drop the weight loss drug Zepbound from its standard formularies on that date, in a blow to its manufacturer, Eli Lilly, a CVS spokesperson told CNBC.